chunk_id large_string | cik large_string | ticker large_string | company_name large_string | sic_code large_string | accession large_string | form_type large_string | filed_at large_string | fiscal_year float64 | fiscal_period large_string | chunk_type large_string | heading large_string | pre_context large_string | text large_string | source_url large_string | facts_count int32 | scale_cue_in_text bool | sample_stratum large_string | facts list | non_target_spans list |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0204bc6c5ba31867024d8a53831d078c06915b6de3e5b4504dc99a90a1bbae1f | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | notes | Loss Per Common Share | 0.01 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted loss per share of common stock for the periods presented because including them would have been anti-dilutive: | |
| Three Months Ended June 30, (Unaudited) | Six Months Ended June 30, (Unaudited) |
| 2022 | 2021 | 2022 | 2021 |
Stock options | 37,755,000 | 21,850,000 | 37,755,000 | 21,850,000 |
Common shares underlying convertible debt | 5,570,932 | 5,213,498 | 5,570,932 | 5,213,498 |
Warrants | 136,187,225 | 50,213,334 | 136,18... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 16 | true | 10-Q|notes|16-40 | [
{
"fact_id": "3eb51fd98246294e9678719d5b9450b872961b52122bc160f214bbf7e1daff14",
"concept": "us-gaap#AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unit": "shares",
"period": "duration:2022-04-01..2022-06-30",
"value": "37755000",
"displayed_text": "37,755,000",
... | [
{
"span_text": "30,",
"start": 28,
"end": 31,
"class": "date"
},
{
"span_text": "30,",
"start": 68,
"end": 71,
"class": "date"
},
{
"span_text": "2022",
"start": 88,
"end": 92,
"class": "year"
},
{
"span_text": "2021",
"start": 95,
"end": 99,
... |
32d15ef96fad7b6065e7317cc67151eb727c35484b5f65d143d9d8319c628e80 | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | mda | General Trends and Outlook | drome, macular degeneration and diabetic retinopathy. Data we presented at the American Association of Pharmaceutical Scientists ("AAPS") meeting held in November 2017 revealed that an early ocular formulation of SBI-200 was able to penetrate multiple compartments of the eye, including reaching the retina and the optic... | The evolving COVID-19 pandemic has prompted governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of business, quarantines, and shelter-in-place orders. The COVID-19 pandemic has significantly curtailed global economic activity and caused s... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 0 | false | abstention|0 | [] | [
{
"span_text": "19",
"start": 19,
"end": 21,
"class": "untagged_amount"
},
{
"span_text": "19",
"start": 243,
"end": 245,
"class": "untagged_amount"
},
{
"span_text": "19",
"start": 396,
"end": 398,
"class": "untagged_amount"
},
{
"span_text": "1",
... |
35c7c6ae4641d006b65e9ffb23be620c7ac396168cb84e155e06d1681bdda369 | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | notes | Fair Value Measurements | es The Company’s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company’s product candidates, uncertainties related to the impact of COVID-19 (Note 1), risks related to operating pri... | Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market partici... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 0 | false | abstention|0 | [] | [
{
"span_text": "1",
"start": 671,
"end": 672,
"class": "note_ref"
},
{
"span_text": "2",
"start": 859,
"end": 860,
"class": "note_ref"
},
{
"span_text": "1",
"start": 898,
"end": 899,
"class": "note_ref"
},
{
"span_text": "3",
"start": 1174,
"e... |
3f59d94778eea08a0272be2c1ba3e1c52c47b10f7062697254e9ea6ce266af61 | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | notes | Liquidity and Going Concern | suffer in the event of continued business interruptions, supply chain issues, delayed clinical trials, production or a lack of laboratory resources due to the pandemic and other global conditions. It is possible that the Company may encounter other similar issues relating COVID-19 or the cyberattack that will need to ... | The Company has made adjustments to its operations designed to keep its employees safe and comply with federal, state and local guidelines. The extent to which COVID-19 may further impact the Company’s business, results of operations, financial condition and cash flows will depend on future developments, which are high... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 0 | false | abstention|0 | [] | [
{
"span_text": "19",
"start": 166,
"end": 168,
"class": "date"
},
{
"span_text": "19,",
"start": 395,
"end": 398,
"class": "untagged_amount"
},
{
"span_text": "100",
"start": 683,
"end": 686,
"class": "untagged_amount"
},
{
"span_text": "19",
"star... |
688c003fac069c4fe55c2884ce1173fd6473083aca4ad629ca122ed9ce8274d9 | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | notes | Stock-Based Compensation Expense | ment activities, other expenses and equipment and laboratory supplies. Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not ... | Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the fair value is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. Upon the exercise of stock option awards, the Company's policy is to issue new shares of its com... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 0 | false | abstention|0 | [] | [
{
"span_text": "718",
"start": 1248,
"end": 1251,
"class": "note_ref"
},
{
"span_text": "718",
"start": 1294,
"end": 1297,
"class": "note_ref"
}
] |
8ada7c5418e0872976da5ea40bc4dc776029c978579ee7c4f6367f6295b601f3 | 0001516551 | SKYE | Skye Bioscience, Inc. | 2834 | 000151655122000022 | 10-Q | 2022-08-15 | 2,022 | Q2 | notes | Asset Acquisition | — 4,000,000 — Asset Acquisition | The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in ... | https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm | 0 | false | abstention|0 | [] | [] |
0342ef757ebaf32b996f6dd646ead2b83f99eac55d6b7cde7a09fb502a150711 | 0000318833 | TISI | TEAM, INC. | 7600 | 000031883323000018 | 10-Q | 2023-05-11 | 2,023 | Q1 | table_context | (in thousands, except share and per share data) (part 2) | 1 Table of Contents PART I—FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS TEAM, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) | |
| March 31, 2023 | December 31, 2022 |
ASSETS | (unaudited) |
Current assets: |
Cash and cash equivalents | $ | 31,869 | $ | 58,075 |
Accounts receivable, net of allowance of $ 4,926 and $ 5,262 respectively
| 178,211 | 186,689 |
Inventory | 37,998 | 36,331 |
Income tax receivable | 828 | 779 |
Prepaid expenses and o... | https://www.sec.gov/Archives/edgar/data/0000318833/000031883323000018/tisi-20230331.htm | 74 | true | 10-Q|table_context|41+ | [
{
"fact_id": "a047f54206c375a9d476c65a0af937de582b582dfc8f55297db8ea0fabfbf9fa",
"concept": "us-gaap#CashAndCashEquivalentsAtCarryingValue",
"unit": "monetary:USD",
"period": "instant:2023-03-31",
"value": "31869000",
"displayed_text": "31,869",
"text_start": 114,
"text_end": 120,
... | [
{
"span_text": "31,",
"start": 10,
"end": 13,
"class": "date"
},
{
"span_text": "2023",
"start": 14,
"end": 18,
"class": "year"
},
{
"span_text": "31,",
"start": 30,
"end": 33,
"class": "date"
},
{
"span_text": "2022",
"start": 34,
"end": 38,
... |
0006f990a30c707617596836a4cde3f05c235bd062e31a37d4b47f07fce2161a | 0000894627 | EGY | VAALCO Energy, Inc. | 1311 | 000143774923030706 | 10-Q | 2023-11-08 | 2,023 | Q3 | table_context | null | $ 120 $ 121,612 11 Table of Contents | (in thousands)
| | Gabon
| | | Egypt
| | | Canada
| | | Equatorial Guinea
| | | Corporate and Other
| | | Total
| |
Long-lived assets from continuing operations:
| | | | | | | | | | | | | | | | | | | | | | | | |
As of September 30, 2023
| | $ | 1... | https://www.sec.gov/Archives/edgar/data/894627/000143774923030706/0001437749-23-030706-index.htm | 12 | true | 10-Q|table_context|6-15 | [
{
"fact_id": "9e3bd0fcf030c8248de40787d68715483bc333ef5ddf9ca7aaefbf92752266e5",
"concept": "us-gaap#NoncurrentAssets",
"unit": "monetary:USD",
"period": "instant:2023-09-30",
"value": "186966000",
"displayed_text": "186,966",
"text_start": 319,
"text_end": 326,
"dimensions": [
... | [
{
"span_text": "30,",
"start": 300,
"end": 303,
"class": "date"
},
{
"span_text": "2023",
"start": 304,
"end": 308,
"class": "year"
},
{
"span_text": "31,",
"start": 453,
"end": 456,
"class": "date"
},
{
"span_text": "2022",
"start": 457,
"end"... |
03be970c222e5c60e03ed31020983ebdc0bb95aaa9740733b1e27152dd725903 | 0001037540 | BXP | BOSTON PROPERTIES, INC. | 6798 | 000165642320000007 | 10-K | 2020-03-02 | 2,019 | FY | notes | 16. Stock Option and Incentive Plan | 2.68 % , 2.63 % and 2.14 % and an expected price volatility of 27.0 % , 27.0 % and 28.0 % , respectively. | There were no non-qualified stock options granted during the years ended December 31, 2019 , 2018 and 2017 .
A summary of the status of Boston Properties, Inc.’s stock options as of December 31, 2019 , 2018 and 2017 and changes during the years then ended are presented below:
| Shares
| Weighted-Average
Exercise Price
... | https://www.sec.gov/Archives/edgar/data/1037540/000165642320000007/bxpandbplp201910-k.htm | 15 | false | 10-K|notes|6-15 | [
{
"fact_id": "631bdb359ae290e18c4c7faf86e59937e4d4cb73a47938f2564a48281ce3386d",
"concept": "ext-0001037540#NonQualifiedStockOptionsIssued",
"unit": "shares",
"period": "instant:2019-12-31",
"value": "0",
"displayed_text": "no",
"text_start": 11,
"text_end": 13,
"dimensions": [],... | [
{
"span_text": "31,",
"start": 82,
"end": 85,
"class": "date"
},
{
"span_text": "2019",
"start": 86,
"end": 90,
"class": "year"
},
{
"span_text": "2018",
"start": 93,
"end": 97,
"class": "year"
},
{
"span_text": "2017",
"start": 102,
"end": 106... |
000a334a4124ccdc983d3a3b71f9c32d69b6bf516742e2582f164fa567d9d3f5 | 0000912593 | SUI | SUN COMMUNITIES, INC | 6798 | 000091259321000185 | 10-Q | 2021-07-27 | 2,021 | Q2 | table_context | (Unaudited) | three reportable segments are: (i) Manufactured home ("MH") communities, (ii) Recreational vehicle ("RV") resorts and (iii) Marinas. 7 SUN COMMUNITIES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued) (Unaudited) 2. Revenue The following tables detail our revenue by major source (in thousands): | |
| Three Months Ended |
| June 30, 2021 | June 30, 2020 (1)
| MH | RV | Marina | Consolidated | MH | RV | Marina | Consolidated |
Revenues |
Real property | $ | 199,948 | $ | 132,463 | $ | 73,494 | $ | 405,905 | $ | 181,713 | $ | 69,414 | N/A | $ | 251,127 |
Home sales | 69,922 | 11,926 | — | 81,848 | 35,074 | 3,456 |... | https://www.sec.gov/Archives/edgar/data/912593/000091259321000185/sui-20210630.htm | 42 | true | 10-Q|table_context|41+ | [
{
"fact_id": "fa6e924b9fa6ead4393985ee1a3b48f4c75aa78604df41b712fafe0d8be4c01b",
"concept": "us-gaap#RevenueFromContractWithCustomerIncludingAssessedTax",
"unit": "monetary:USD",
"period": "duration:2021-04-01..2021-06-30",
"value": "199948000",
"displayed_text": "199,948",
"text_start":... | [
{
"span_text": "30,",
"start": 32,
"end": 35,
"class": "date"
},
{
"span_text": "2021",
"start": 36,
"end": 40,
"class": "year"
},
{
"span_text": "30,",
"start": 48,
"end": 51,
"class": "date"
},
{
"span_text": "2020",
"start": 52,
"end": 56,
... |
01c3b32aae1572a6376c0efb52643a5b1e6f7787bb485dbb16bee1edea25ac94 | 0001646972 | ACI | Albertsons Companies, Inc. | 5411 | 000164697219000054 | 10-Q | 2019-07-24 | 2,019 | Q1 | notes | Significant Accounting Policies | or omitted for the interim periods presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). In the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the i... | Restricted cash: Restricted cash is included in Other current assets or Other assets depending on the remaining term of the restriction and primarily relates to funds held in escrow. The Company had $ 51.6 million and $ 41.6 million of restricted cash as of June 15, 2019 and February 23, 2019 , respectively.
Inventorie... | https://www.sec.gov/Archives/edgar/data/1646972/000164697219000054/aciq1-1910xq.htm | 5 | false | 10-Q|notes|2-5 | [
{
"fact_id": "aca671ed3283e29ffcb40b76f8cfe8f41babf9bd91e852706e2d1824a48eb893",
"concept": "us-gaap#RestrictedCash",
"unit": "monetary:USD",
"period": "instant:2019-06-15",
"value": "51600000",
"displayed_text": "51.6",
"text_start": 201,
"text_end": 205,
"dimensions": [],
"... | [
{
"span_text": "15,",
"start": 263,
"end": 266,
"class": "date"
},
{
"span_text": "2019",
"start": 267,
"end": 271,
"class": "year"
},
{
"span_text": "23,",
"start": 285,
"end": 288,
"class": "date"
},
{
"span_text": "2019",
"start": 289,
"end"... |
001ac321bf1bd1277c042710397044521f0653f5ba6e5e308165678257e54844 | 0001295810 | SHO | Sunstone Hotel Investors, Inc. | 7011 | 000110465926055508 | 10-Q | 2026-05-05 | 2,026 | Q1 | table_context | null | Table of Contents SUNSTONE HOTEL INVESTORS, INC. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Supplemental Disclosure of Cash Flow Information March 31, 2026 2025 Cash and cash equivalents $ 91,134 $ 72,334 Restricted cash 75,549 76,460 Total cash and cash equivalents and restricted cash shown on the ... | | Three Months Ended March 31,
| 2026
| 2025
Cash paid for interest, net of capitalized interest
| $
| 15,150
| $
| 13,004
Cash paid (refunded) for income taxes, net
| $
| 70
| $
| ( 145 )
Changes in operating lease right-of-use assets
| $
| 320
| $
| 1,203
Changes in operating lease obligations
| ( 537 )
| ( 1,344 )
C... | https://www.sec.gov/Archives/edgar/data/0001295810/000110465926055508/sho-20260331x10q.htm | 10 | true | 10-Q|table_context|6-15 | [
{
"fact_id": "a7abf848f167695698f307823ed1f741be89018ad06eda173222d1c1a577bbcd",
"concept": "us-gaap#InterestPaidNet",
"unit": "monetary:USD",
"period": "duration:2026-01-01..2026-03-31",
"value": "15150000",
"displayed_text": "15,150",
"text_start": 103,
"text_end": 109,
"dimens... | [
{
"span_text": "31,",
"start": 27,
"end": 30,
"class": "date"
},
{
"span_text": "2026",
"start": 33,
"end": 37,
"class": "year"
},
{
"span_text": "2025",
"start": 40,
"end": 44,
"class": "year"
}
] |
000b05069e23cf0959ece65864c5d3f954e763fe7c5fddc008b1258044689723 | 0001032208 | SRE | SEMPRA ENERGY | 4932 | 000008652118000091 | 10-Q | 2018-11-07 | 2,018 | Q3 | table_context | Sempra Energy | 74 LONG-TERM DEBT Sempra Energy On January 12, 2018, we issued the following debt securities and received net proceeds of $ 4.9 billion (after deducting discounts and debt issuance costs of $ 68 million ): | |
NOTES ISSUED IN LONG-TERM DEBT OFFERING
(Dollars in millions)
Title of each class of securities
| Aggregate principal amount
| Maturity
| Interest payments
Floating Rate (1) Notes due 2019
| $
| 500
| July 15, 2019
| Quarterly
Floating Rate (2) Notes due 2021
| 700
| January 15, 2021
| Quarterly
2.400% Senior Notes d... | https://www.sec.gov/Archives/edgar/data/1032208/000008652118000091/0000086521-18-000091-index.htm | 7 | true | 10-Q|table_context|6-15 | [
{
"fact_id": "8b9213ab3602439655a56195021f31c87fcc9e7d5a8a36ddf766a4e130a501f6",
"concept": "us-gaap#DebtInstrumentFaceAmount",
"unit": "monetary:USD",
"period": "instant:2018-01-12",
"value": "500000000",
"displayed_text": "500",
"text_start": 197,
"text_end": 200,
"dimensions":... | [
{
"span_text": "(1)",
"start": 172,
"end": 175,
"class": "other"
},
{
"span_text": "2019",
"start": 186,
"end": 190,
"class": "year"
},
{
"span_text": "15,",
"start": 208,
"end": 211,
"class": "date"
},
{
"span_text": "2019",
"start": 212,
"end... |
090432c6604a8e91712f65765aa2da08d499edd418b14821c09f1592a508375a | 0001596812 | ENLV | Enlivex Therapeutics Ltd. | 2834 | 000121390023028398 | 20-F | 2023-04-10 | 2,022 | FY | table_context | Research and development expenses – net | NOTE 16 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Research and development expenses – net | Year
ended December 31, |
(in thousands ) |
2022 |
2021 |
2020 |
Payroll and related expenses |
$ | 6,371 |
$ | 5,054 |
$ | 3,183 |
Research and development services |
| 8,264 |
| 4,557 |
| 2,438 |
Materials |
| 2,044 |
| 1,505 |
| 612 |
Share Based Compensation |
| 876 |
| 1,210 |
| 401 |
Depreciation |
| 740 |
| 546 ... | https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/0001213900-23-028398-index.htm | 27 | true | 20-F|table_context|16-40 | [
{
"fact_id": "13fb38cc775ab5160100e7233188ec635e746412d33922385cb825faefeb9272",
"concept": "us-gaap#AccruedPayrollTaxesCurrent",
"unit": "monetary:USD",
"period": "instant:2022-12-31",
"value": "6371000",
"displayed_text": "6,371",
"text_start": 100,
"text_end": 105,
"dimensions... | [
{
"span_text": "31,",
"start": 20,
"end": 23,
"class": "date"
},
{
"span_text": "2022",
"start": 44,
"end": 48,
"class": "year"
},
{
"span_text": "2021",
"start": 51,
"end": 55,
"class": "year"
},
{
"span_text": "2020",
"start": 58,
"end": 62,
... |
43c3b0b24c2c1abfc7381d3eea374e8505e7d04661ce3174505ea08dff0b46f6 | 0001302215 | HLI | Houlihan Lokey, Inc. | 6282 | 000130221520000074 | 10-K | 2020-05-15 | 2,020 | FY | table_context | null | er the 2016 Incentive Plan by approximately 12.2 million shares. Under the Amendment, the aggregate number of shares of common stock that are available for issuance under awards granted pursuant to the 2016 Incentive Plan is equal to the sum of (i) 8.0 million and (ii) any shares of our Class B common stock that are su... | |
•
| 6,540,659 shares of our Class A common stock and Class B common stock; | https://www.sec.gov/Archives/edgar/data/1302215/000130221520000074/0001302215-20-000074-index.htm | 1 | false | 10-K|table_context|1 | [
{
"fact_id": "a47bb0c79b79e06f24cad98a6afaf2b94021075ea987daf432355795abbf81a7",
"concept": "ext-0001302215#ShareBasedCompensationArrangementBySharebasedPaymentAwardIncreaseDecreaseToNumberofSharesAuthorized",
"unit": "shares",
"period": "instant:2017-10-19",
"value": "6540659",
"displayed_t... | [] |
00186790c8733c2217e890362bb3122b5396dae770c419e1f7f3d670cecd91f1 | 0001464865 | ASII | Accredited Solutions, Inc. | 2080 | 000147793222002592 | 10-K | 2022-04-25 | 2,021 | FY | notes | NOTE 10 – JOINT VENTURE | in convertible debt. See Note 5. On November 17, 2021, the Company issued 83,043 shares of common stock to GS Capital, LLC for a conversion of $ 8,745 in convertible debt. See Note 5. On December 13, 2021, the Company issued 224,964 shares of common stock to GS Capital, LLC for a conversion of $ 8,774 in convertible de... | On August 24, 2020, with an effective date of July 1, 2020, the Company entered into a joint venture agreement with Paul Hervey (“Hervey”) for the purpose of cultivating hemp. Hervey is a licensed hemp cultivator in good standing under the laws of North Carolina with approximately 3,700 square feet of greenhouse cultiv... | https://www.sec.gov/Archives/edgar/data/0001464865/000147793222002592/ghmp_10k.htm | 8 | false | 10-K|notes|6-15 | [
{
"fact_id": "e5b0364f63359a1dc6aee3a839da22648e1e94b42ffea2dc120ba3cd551cec9a",
"concept": "us-gaap#ContributionOfProperty",
"unit": "monetary:USD",
"period": "duration:2020-08-02..2020-08-24",
"value": "160000",
"displayed_text": "160,000",
"text_start": 462,
"text_end": 469,
"... | [
{
"span_text": "24,",
"start": 10,
"end": 13,
"class": "date"
},
{
"span_text": "2020,",
"start": 14,
"end": 19,
"class": "year"
},
{
"span_text": "1,",
"start": 51,
"end": 53,
"class": "date"
},
{
"span_text": "2020,",
"start": 54,
"end": 59,
... |
FiledFact-Passages - passage-complete, span-grounded SEC fact extraction
5,698 SEC filing passages containing 101,899 financial facts - every fact grounded to its exact characters, every other numeric span labeled as a non-target, and every fact linked to the exact number in the original filing.
Each row contains one clean filing passage (financial-statement tables, notes, or MD&A) and every tagged fact displayed in it: concept, normalized full-unit value, period, unit, decoded dimensions, exact character offsets, and an evidence_url that opens the filing at that number. Years, dates, references, prose percentages, and untagged amounts are labeled in non_target_spans.
- Sibling dataset: FiledFact-100K provides one grounded fact per row.
- Companion model: FiledFact-Qwen3-8B.
from datasets import load_dataset
ds = load_dataset("StockAlloy/filedfact-passages")
row = ds["validation"][0]
for fact in row["facts"]:
assert row["text"][fact["text_start"]:fact["text_end"]] == fact["displayed_text"]
| Count | |
|---|---|
| Passages | 5,698 |
| Companies | 4,878 |
| Tagged facts | 101,899 |
| Non-target numeric spans | 50,658 |
The task
Input: one filing passage, with optional nearby context.
Output: every tagged financial fact displayed in the passage.
A validation example is a goodwill-by-segment table whose pre_context says “In thousands”:
Engineering
| | | Specialty
Health Care
| | | Information
Technology
| | | Total
$ | 11,918 | | | $ | 2,398 | | | $ | 7,831 | | | $ | 22,147 |
Its four facts:
{"concept": "us-gaap#Goodwill", "value": "11918000", "unit": "monetary:USD",
"period": "instant:2023-04-01", "text_start": 97, "text_end": 103,
"dimensions": [{"axis": "StatementBusinessSegmentsAxis",
"member": "ext-0000700841#EngineeringMember"}]}
{"concept": "us-gaap#Goodwill", "value": "2398000", "unit": "monetary:USD",
"period": "instant:2023-04-01", "text_start": 118, "text_end": 123,
"dimensions": [{"axis": "StatementBusinessSegmentsAxis",
"member": "ext-0000700841#SpecialtyHealthCareMember"}]}
{"concept": "us-gaap#Goodwill", "value": "7831000", "unit": "monetary:USD",
"period": "instant:2023-04-01", "text_start": 138, "text_end": 143,
"dimensions": [{"axis": "StatementBusinessSegmentsAxis",
"member": "ext-0000700841#InformationTechnologyMember"}]}
{"concept": "us-gaap#Goodwill", "value": "22147000", "unit": "monetary:USD",
"period": "instant:2023-04-01", "text_start": 158, "text_end": 164,
"dimensions": []}
The displayed 11,918 means 11918000 because the scale cue is in the nearby context. The segment cells carry dimensions; the total has an empty dimensions list.
Some passages intentionally contain no target facts (labeled abstention|0 in sample_stratum).
What passage-complete means
Each passage contains:
facts- the financial facts to extract (the numbers the filer tagged in the filing).non_target_spans- every other numeric span, including years, dates, references, prose percentages, and untagged amounts.
A visible numeric token is assigned to one of those two groups. Co-located XBRL facts are kept separately when the filer attached multiple concepts, periods, or dimensions to the same displayed number.
Values and evidence
displayed_textis exactly what appears in the passage.text_startandtext_endare half-open character offsets intotext.valueis the normalized full-unit value after applying sign, scale, and numeric format.dimensionsrecords business segment, product, geography, investment, or another dimensional scope.evidence_urlopens the corresponding number in the filing;source_urlpoints to the SEC document.
XBRL labels are provided as reported by the filer and may reflect errors in the source filing.
Files and schema
| Split | Passages | Companies | Facts | Typed-dimension facts |
|---|---|---|---|---|
| Train | 4,922 | 4,113 | 87,539 | 4,181 |
| Validation | 776 | 765 | 14,360 | 375 |
| Total | 5,698 | 4,878 | 101,899 | 4,556 |
Train and validation are company-disjoint. The default files contain one nested row per passage; the flat/ directory provides equivalent passage, fact, and non-target tables.
Passage fields
| Field | Description |
|---|---|
chunk_id |
Stable passage ID and flat-table join key |
cik, ticker, company_name, sic_code |
Issuer identity |
accession, form_type, filed_at |
Filing identity |
fiscal_year, fiscal_period |
Filing-level fiscal focus |
chunk_type, heading, pre_context |
Passage location and nearby context |
text |
Clean passage text; table cells are separated with vertical bars |
source_url |
SEC filing URL |
facts_count |
Number of target facts |
scale_cue_in_text, sample_stratum |
Presentation and sampling metadata |
facts |
Nested target-fact records |
non_target_spans |
Nested non-target numeric spans |
Fact fields
| Field | Description |
|---|---|
fact_id |
Stable fact ID |
concept |
Namespace-qualified XBRL concept |
period |
instant:DATE or duration:START..END |
value |
Precision-preserving normalized value |
unit |
Examples: monetary:USD, per_share:USD, shares, pure |
displayed_text |
Exact characters shown in the passage |
text_start, text_end |
Character offsets into text |
scale |
Power-of-ten presentation scale |
decimals, format |
Filing rounding and numeric-format metadata |
dimensions |
Explicit or typed dimensional scope |
evidence_url |
Link to the corresponding filing location |
Each non_target_spans record contains span_text, start, end, and class.
Companion model
The companion model's training data includes these passages, so evaluating it on this dataset would be in-sample. Use separate held-out data for evaluation. The extraction prompt, output format, benchmark protocol, and model results are on the model card.
License and access
This sample is licensed under CC BY-NC 4.0. The license applies to StockAlloy's compilation, annotations, alignments, and derived metadata. The original SEC filings remain independently available through EDGAR.
Contact: data@stockalloy.com.
Evidence links are intended for inspection and light programmatic use. Contact StockAlloy before bulk retrieval.
- Dataset version: v1.2
- Selection manifest SHA-256:
bc0b3e526742567daa5b17deacb533a4419e5cab4375962cdb5a0e0a7ef78a3a
@dataset{stockalloy_filedfact_passages_2026,
title = {FiledFact-Passages: Passage-Complete, Span-Grounded SEC Financial Facts},
author = {StockAlloy Research},
year = {2026},
url = {https://huggingface.co/datasets/StockAlloy/filedfact-passages}
}
- Downloads last month
- 61
